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Background
Vaccination strategies capable of eliciting neutralizing
antibody responses to HIV remain elusive despite exten-
sive efforts. Alternative antibody functions offer opportu-
nities for protection without necessarily achieving broad
neutralization breadth. Viral immune exclusion through
aggregation has been proposed as an alternative protection
pathway, but mechanisms for studying this phenomenon
at the scale necessary for clinical trials have not been
explored.
Methods
Concentrated fluorescent virions of two colors, suspended
in hydroxyethylcellulose (HEC) gel, which has been for-
mulated to simulate the diffusion characteristics of cervical
mucus, are imaged over time. Mean squared displacement
and incidence of colocalized viral particles are determined.
The addition of monoclonal antibodies of various specifici-
ties and isotypes affects these parameters is explored.
Immunoglobulin isolated from HIV-1 positive individuals
was examined as well. Correlative scanning electron
micrographs of the same preparations were performed to
confirm the nature of suspected aggregates.
Results
Multimeric antibodies, rather than monomeric isoforms,
selectively hinder the diffusion characteristics of coloca-
lized virions, more so than non-aggregated virions. The
incidence of colocalized virions is also increased in a con-
centration dependent manner. Excessive antibody or virus
concentration is seen to obviate aggregate formation.
These results are seen in both monoclonal antibody
experiments alongside polyclonal patient IgA isolated
from breast milk and IgM from serum.
Conclusion
Virus aggregation has been demonstrated as a feasible
effector function of HIV-1 specific antibody preparations.
This assay platform is amenable to adaptation for medium
to high throughput sample screening and low sample size.
Monoclonal antibodies as well as patient samples are able
to induce similar behaviors. Measurement of viral aggrega-
tion as a corollary of vaccine efficacy is deserving of
further exploration in a clinical setting.
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